Type I interferons (IFNs) are pleiotropic cytokines that modulate both innate and adaptive immune responses. They have been used to treat autoimmune disorders, cancers, and viral infection and have been demonstrated to elicit differential responses within cells, despite sharing a single receptor. The molecular basis for such differential responses has remained elusive. To identify the mechanisms underlying differential type I IFN signaling, we used whole genome microarrays to measure longitudinal transcriptional events within human CD4 ϩ T cells treated with IFN-␣2b or IFN-␤1a. We identified differentially regulated genes, analyzed them for the enrichment of known promoter elements and pathways, and constructed a network module based on weighted gene coexpression network analysis (WGCNA). WGCNA uses advanced statistical measures to find interconnected modules of correlated genes. Overall, differential responses to IFN in CD4 ϩ T cells related to three dominant themes: migration, antigen presentation, and the cytotoxic response. For migration, WGCNA identified subtypespecific regulation of pre-mRNA processing factor 4 homolog B and eukaryotic translation initiation factor 4A2, which work at various levels within the cell to affect the expression of the chemokine CCL5. WGCNA also identified sterile ␣-motif domain-containing 9-like (SAMD9L) as critical in subtype-independent effects of IFN treatment. RNA interference of SAMD9L expression enhanced the migratory phenotype of activated T cells treated with IFN-␤ compared with controls. Through the analysis of the dynamic transcriptional events after differential IFN treatment, we were able to identify specific signatures and to uncover novel genes that may underpin the type I IFN response.
INTERFERONS (IFNs) are pleiotropic molecules implicated in a wide range of cellular responses (44) and are Federal Drug Administration-approved therapeutics for the treatment of cancer, infection, and autoimmunity (49) . Based on sequence homology and structure, IFNs are divided into three classes: types I, II, and III. Type I IFNs include IFN-␣ (15 known ␣-subtypes), IFN-␤, and IFN-, whereas type II IFN consists only of IFN-␥ and type III IFN consists only of IFN-. All type I IFNs activate a common cell surface receptor [the IFN receptor (IFNR)], which exists as two separate polypeptides (IFNAR1 and IFNAR2) with no intrinsic dimerization capacity (12) . Binding of type I IFNs to IFNAR2, recruitment of IFNAR1, and stabilization of a heterotrimeric ligand/receptor complex activate members of the Jak1/tyrosine kinase 2 (Tyk2) and JAK/STAT pathways (12, 45) . Phosphorylated STAT1/ STAT2 heterodimers form transcriptional activation complexes with IFN regulatory factor (IRF)9/p48, translocate to the nucleus, and drive the expression of numerous genes, including myxovirus resistance protein 1 (MX1), 2Ј,5Ј-oligoadenylate synthetase 1, and double-stranded RNA-activated protein kinase (EIF2AK2).
Although type I IFNs share the same cognate receptor and underlying canonical activation cascade (54) , they have been shown to elicit differential cellular responses (66) . For example, IFN-␤, but not IFN-␣ or IFN-, was able to induce the phosphorylation of an IFNAR1-associated subunit (1, 62) later identified as IFNAR-2c (15) . The TYK2-deficient cell line U1A was responsive to IFN-␤ but not to IFN-␣ 2 (25, 63) , and IFN-␤ has been shown to be 100-fold more potent than IFN-␣ 2 at inhibiting the differentiation of human monocytes into osteoclasts (11) . These differences persist even within a single IFN subfamily. Treatment of Daudi and AU937 cells with 21 different purified IFN-␣ proteins produced a range of antiproliferative activities spanning at least three orders of magnitude (33) . Moreover, differences can be detected at the transcriptional level, where different IFN subtypes trigger largely similar, but not identical, microarray expression profiles (16, 19, 39) . Finally, there is a notable difference underlying patient tolerability to IFNs. IFN-␣, used in treatments of melanoma, T cell lymphomas, and hepatitis C virus, induces a more frequent and diverse range of side effects including fatigue, myalgia, depression, sexual and sleep disorders, and flu-like symptoms that often precipitate patient voluntary withdrawal (30) .
The nature of the biological diversity intrinsic to type I IFN signaling is still controversial, although it appears that these differential signaling responses can be attributed in part to mRNA splicing variation and ligand affinity. A splice variant of IFNAR1, lacking one of the four extracellular repeat domains, is differentially responsive to a subset of the INF-␣ subfamily compared with the full-length polypeptide (14, 20) . Moreover, IFN-␤ has been shown to possess an ϳ50-fold higher affinity for IFNAR1 than IFN-␣ 2 (26, 45) , and only IFN-␣ has been shown to induce IFNAR2 receptor recycling (50) . Finally, mutations of conversed ligand/receptor interface amino acids on IFN-␣ 2 resulted in an activity profile characteristic of IFN-␤, including higher affinity, enhanced receptor/ ligand complex stabilization, antiviral and antiproliferative properties, and similar transcriptional response profiles (39) .
However, despite the identification and functional classification of several IFN-inducible genes, clear subcellular mechanisms relevant to disease treatment have not yet been elucidated. Previous studies using cross-sectional, single-time point comparisons have not addressed the underlying dynamic nature of the cellular response and overarching pathways that govern the changes in transcript expression. In this study, we used microarray technology to measure global transcriptional responses of CD4 ϩ T cells over a time series after both IFN-␣ 2b and IFN-␤ 1a treatment. We analyzed differentially expressed genes (DEG) and interrogated those DEGs for the enrichment of known transcription factor-binding sites (TFBSs) and pathways. We constructed networks based on unbiased weighted gene coexpression network analysis (WGCNA) that correspond to general and specific IFN responses. Through the use of a time series as well as by comparing and contrasting IFN-␤ 1a -and IFN-␣ 2b -evoked responses, we were able to identify kinetic differences between IFN subtypes and specific pathways after IFN stimulation and discover several genes novel to IFN signaling that may represent attractive candidates in the formulation of new therapies for disease treatment.
MATERIALS AND METHODS

Cell culture and isolation. CD4
ϩ T cells were isolated from peripheral blood mononuclear cells (PBMCs) of one healthy donor (white male, 32 yr old, with no familial history of immune-related diseases) using the Dynal CD4 ϩ T cell negative isolation kit (Invitrogen). The resultant population of stimulated cells were 95% CD3 ϩ and 98% CD4 ϩ (data not shown) when analyzed by FACS. PBMCs were isolated from whole blood using Ficoll-Paque Plus (GE Healthcare) following the manufacturer's recommended protocol. Before IFN stimulation, 1 ϫ 10 7 cells were cultured in RPMI-1640 (Invitrogen) and supplemented with 10% FCS (Gemini Bioproducts) and 1ϫ penicillin-streptomycin (Invitrogen) for a period of 2 h. Cells were either untreated or treated with 1,000 U/ml of either IFN-␤ 1a or IFN-␣2b (Cell Sciences) for 1, 3, 6, 9, or 12 h and were harvested for RNA extraction (see RNA isolation and microarray analysis). IFN-␤ 1a-treated cells were processed as biological duplicates; all IFN-␣2b-treated cells were processed as biological triplicates. In the WGCNA analysis, we included IFN-␤ 1a-treated Jurkat and CEM cell lines processed as described above. For activated T cells, PBMCs were activated with 3 g/ml phytohemagglutinin (Roche) and 25 U/ml human recombinant (r)IL-2 (Invitrogen) for 3 days followed by 2 days of human rIL-2. The resultant population of stimulated cells was 95% CD3 ϩ , 70% CD8 ϩ , 30% CD4 ϩ , and 70% CD25 ϩ (data not shown) when analyzed by FACS.
RNA isolation and microarray analysis. Total RNA was extracted using TRIzol reagent (Invitrogen) following the manufacturer's recommended protocol. Total RNA was cleaned using the RNeasy Kit (Qiagen). For microarray analysis, 5 g of total RNA were sent to the Translational Genomics Research Institute (Phoenix, AZ) and assayed using the HG-U1133 Plus 2.0 GeneChip system (Affymetrix). The resultant microarray .cel files were subject to quality control using the Bioconductor (27) packages: AffyQCreport (24) and AffyPLM (37) . All arrays adhered to author-recommended quality control thresholds, including GAPDH and ␤-actin 3Ј/5Ј-probeset ratios, array scaling factors, mean array intensity distributions, and positive/negative edge elements. Probesets were annotated using version 24 of the Affymetrix probeset annotation file (see Supplemental Table 1 for probeset annotations used), with some manual annotation using GeneAnnot (8) . 1 RNA interference transfection and proliferation/migration assays. IFN-␤1a was used at 1,000 U/ml as indicated. For transfection, activated T cells were prestimulated with or without IFN-␤1a for 3 h. T cells were then transfected with either 33 pmol (ϳ0.5 g) of RNA inhibitor (control or target, Invitrogen) or mock (water) using the Amaxa Nucleofector system (Lonza) and the T Cell Nucleofector kit according to the manufacturer-suggested protocols. For oligonucleotide controls, we used the Invitrogen-recommended negative controls. After transfection, cells were cultured in RPMI-1640 (without cytokines, rIL-2, and IFN-␤1a) for 6 h, at which time the media were replaced, cytokines were reintroduced, and cells were cultured for an additional 18 h before being assayed. To assess migration, 1 ϫ 10 transfected T cells in RPMI-1640 containing 25 U/ml human rIL-2 were seeded into the upper chamber of 24-well (3-m pores, BD Biosciences) cell culture inserts with or without IFN-␤ 1a. The lower chamber contained RPMI-1640 supplemented with 100 ng/ml CXCL12 (SDF-1␣, Cell Sciences) with or without IFN-␤ 1a. Cells were allowed to migrate for 24 h, at which time cell numbers in the lower chamber were quantified using the Cyquant Cell Proliferation Assay kit (Invitrogen).
RNA for quantitative RT-PCR (see Quantitative RT-PCR for microarray validation) was extracted from an aliquot of posttransfected cells using the RNeasy Kit (Qiagen) before the beginning of the migration assay (i.e., at 24 h posttransfection).
Quantitative RT-PCR for microarray validation. RNA quantitation was determined by TaqMan Gene Expression assays (Applied Biosystems, ABI) on an ABI 7900HT Sequence Detection System following all manufacturers' protocol. Assays were performed in triplicate using 1 ng RNA/reaction. A log 10 GAPDH dilution series was used to calculate equivalent copy numbers for each reaction (Supplemental Fig. 1 ).
Data and statistical analysis. Expression data were extracted from Affymetrix .cel files using the BRB-ArrayTools Microsoft Excel plug-in (56a). The microarray .cel files were background corrected, normalized, and summarized using the robust multiarray analysis algorithm (6). To identify DEGs over time, a class comparison (F-test) was run to control for the proportion of false discoveries (0.1). When comparisons were made between IFN subtypes, intensity values were normalized to time 0 to account for any baseline differences.
Principal component analysis (PCA) and hierarchical clustering (Euclidean distance metric) were performed with the Multiple Experiment Viewer (70) . Pathway enrichment analysis was done with the DAVID functional annotation tool (18) and the Pathway-Express profiling tool (21) using default parameters. Pajek (4) and Cytoscape (73) were used for network visualization, analysis, and image creation. To identify and visualize differences in IFN-␣ and IFN-␤ expression, we calculated a normalized differential longitudinal expression index, which was calculated as the difference between the normalized sum of all time 0-subtracted expression values over time for IFN-␣ and IFN-␤ treatments (see the Supplemental Material for a complete description). Graphs and tables were created using Microsoft Excel. P values were calculated using either the Microsoft Excel data analysis add-in or the R software environment (www. R-project.com) (64) .
WGCNA. WGCNA was performed as previously described (51, 57, 77) using either CD4 ϩ T cells alone (subtype-specific response) or an expanded panel of cells including CD4 ϩ T cells, PBMCs, and CEM/ Jurkat cell lines. First, probesets called present in Ͻ50% of all arrays were removed, leaving 17,936 probesets for the IFN general response analysis and 16,002 for the subtype-specific response analysis. After the gene list had been finalized, the correlation matrix was obtained by calculating pair-wise Pearson correlations between all variable probesets across all arrays. Next, the adjacency matrix was calculated by raising the absolute values of the correlation matrix to a power of 6 for the IFN-specific network and a power of 12 for the subtype-specific network (77) . Topological overlap (TO) was calculated by comparing connections strengths between a pair of genes to all other genes in the network. To define modules, average linkage hierarchical clustering was applied using 1 Ϫ TO as the distance measure and the application of a height cutoff for the resulting dendrogram (0.96 for both analyses).
RESULTS
Transcriptome overview. The temporal transcriptional events associated with IFN-␤ 1a (henceforth, IFN-␤) or IFN-␣ 2b (henceforth, IFN-␣) treatment in CD4 ϩ T cells were measured using microarray technology. Cells were treated in vitro following a time course of 0 (no treatment, baseline), 1, 3, 6, 9, or 12 h (Fig. 1A) , at which times total RNA was extracted and gene expression was measured. We validated several randomly selected genes by quantitative RT-PCR (Supplemental Fig. 1 ).
To gauge how the expression variances segregated treatment and time points, we applied PCA for samples and hierarchical clustering for genes. PCA clustered samples by IFN subtype and array replicate as well as by spatially disseminating them relative to their treatment length (Fig. 1B) . Hierarchical clustering of genes revealed that the pattern of the IFN-␤ CD4 ϩ T cell response was preserved across most genes when cells were treated with either IFN (Fig. 1C) . The expression of a representative group of known IFN-stimulated genes was similar for both treatments; however, certain genes [e.g., suppressor of cytokine signaling 2 (SOCS2)] showed specific regulatory kinetics specific to each IFN subtype (Fig. 1D) .
To make comparisons based on biological pathways and gene network analyses, we first identified DEG transcripts. Class comparisons by time identified 1,157 transcripts for IFN-␤ treatment, 1,133 of which were also regulated after IFN-␣ treatment and 24 that were unique to IFN-␤ (see the Supplemental Material and Supplemental Fig. 2 ). By analyzing their kinetic profiles, we discovered that most transcriptional responses differed in rate and range, with almost no difference in the response direction (Supplemental Fig. 3) .
Enriched TFBSs. To gain insight into the mechanisms that underlie these transcriptional responses, we searched for TFBSs within the 1,000 bp upstream sequences of the 1,133 common DEGs using CARRIE (31) . CARRIE accounts for not only transcript identity but also significance and fold change over time. Using the default thresholds for significance (corrected P value of 0.01, inclusive all 1,133 DEGs) and a stringent fourfold threshold for up-/downregulation, we identified 56 significant TFBS matrixes from 215 transcripts. After redundancies had been removed, 41 matrixes (25 shared and 16 unique) were highly correlated with IFN stimulation. We plotted the shared matrixes as normalized P value ratios between IFN-␣ and IFN-␤ ( Fig. 2A) and defined Ϯ0.5 (on the normalized Ϫlog 10 scale) as boundaries for higher IFN-␣, similar, or higher IFN-␤ associations ( Fig. 2A) . Many of these shared TFBSs have been previously linked to type I IFN signaling (e.g., STATs and IRFs); however, others were novel associations (aryl-hydrocarbon receptor/aryl-hydrocarbon receptor nuclear translocator). As with the shared TFBSs, many of the subtype-specific TFBSs have previously been linked to T cell regulation and/or IFN induction (e.g., YY1 and STAT4) with some unique associations (MYC-associated zinc finger protein). We also looked for the transcriptional regulation of transcription factors known to bind to the respective sites, which could serve to amplify (upregulation) or repress (downregulation) the transcription of target genes. We found several transcription factors that displayed a significant change in expression over time ( Fig. 2C and Supplemental Fig. 4) . Moreover, we uncovered IFN-subtype dependent expression for the transcription factor genes IRF8, Kruppel-like factor 12 (KLF12), activating transcription factor 2, peroxisome proliferator-activated receptor-␣, and transcription factor 3 (Fig. 2C,  inset) .
Enriched pathways. To determine if the disparities between the type I IFNs could be attributed to known biological pathways, we looked for a significant enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways within the 1,133 overlapping DEGs using a combination of the DAVID functional annotation server (18) and the Pathway-Express profiling tool (21) (Supplemental Material). While no unique KEGG pathways were discovered, we did find notable IFN subtype differences within the antigen processing and presentation (APP), JAK/STAT signaling, and natural killer cell (NKC) pathways (Fig. 3) . For major histocompatability complex (MHC) class II expression within the APP pathway, both IFNs downregulated class II expression (Fig. 3, APP pathway) ; however, the IFN-␣ responses were more prolonged, extending for several hours before saturation. There were also differential responses among JAK/STAT pathway receptors [IL-2 receptor-␣, corticotropin-releasing hormone receptor 2B, and IFN-␥ receptor 1 (IFNGR1)] as well as negative regulators [SOCS2, protein inhibitor of activated STAT 1 (PIAS1), PIAS2, and protein tyrosine phosphatase nonreceptor type 11; Fig. 3 , JAK/STAT pathway]. We also encountered a disparity within the NKC pathway, where IFN-␤ elicited a broad downregulation of component genes and IFN-␣ stimulated the upregulation of inhibitory receptor genes (KIR2DL3 and KIR3DL1) and acti- vation of the repressor gene SH2 domain-containing 1B, the stimulatory receptor genes killer cell lectin-like receptor subfamily D member 1, FCGR3B, and IFNGR1 (see above) as well as spleen tyrosine kinase, granzyme A (GZMA), GZMB, and Fas ligand (FASLG) (Fig. 3, NKC pathway) .
WGCNA. Because KEGG pathways were manually collated from published materials (41), they have a defined architecture determined by biological interactions and are independent of IFN treatment. To put these genes into the perspective of a biological system and to find unbiased transcriptional associations derived from the expression data, we constructed networks using WGCNA. WGCNA uses TO, a measure of a gene's connectivity in the network relative to its neighbors (77) , to organize the network into modules (subnetworks) of tightly coexpressed genes across multiple samples. Using this approach, we discovered two modules (shown in black and red) representative of the general response to IFN and two modules (shown in blue and deep pink) that differentiate subtype responses (Fig. 4 and Supplemental Fig. 5 ).
We used DAVID to identify functional annotation enrichment within these modules (Table 1 and Supplemental Table  3 ). The enrichment of known functional gene annotations within modules provides a validation of WGCNA. The general response black module corresponded to protein catabolism, mRNA processing, and DNA repair, whereas the general response red module was defined by classical IFN signaling categories such as the immune response, apoptosis, and NF-B signaling. The functional composition of the subtype-specific deep pink module was similar to the black module and composed of RNA metabolism and splicing as well as protein metabolic categories. Thus, the same functional categories that correlate with the general IFN response were also able to identify the subtype-specific IFN response, consistent with the previous observation that responses differed mainly by rate, range, and duration. The subtype-specific blue module possessed functional annotations related to several themes, including transcription (RNA binding/processing), transport (protein localization/Golgi transport), and nucleotide binding (kinases).
We used Pajek to identify hubs within each module (Fig. 4) . Hubs are the highly connected nodes within a network that are the hallmark feature of scale-free networks (3). Hubs identified by WGCNA in previous reports have been shown to have a significant impact on the expression of neighboring genes and may be functionally representative of the whole module (32, The general response hubs showed identical upregulated response patterns for both IFNs (Fig. 4 and Supplemental Fig.  5 ). Although GPR155 and LOC646890 have no clear functional annotations, the remaining hubs included functional annotations relating to transcriptional regulation, DNA repair/ recombination, and the regulation of cell proliferation and motility.
The specific response hubs showed the same aforementioned differential transcriptional patterns, namely, differing in their rate and range of expression. Blue module hubs were downregulated and were functionally associated with transcription (CBFB), mRNA processing (PRPF4B), and translation (EIF4A2). The deep pink module was densely connected with marginal separation of hub weights (data not shown); thus, only the top five hubs are discussed. These hubs also showed extensive subtype disparity, where IFN-␣ generally stimulated a slight increase in expression, in contrast to the overall repression stimulated by IFN-␤ treatment (Fig. 4 and Supplemental Fig. 5 ). Within these hubs, BAT2D1, GALNT1, and RBM25 were significantly different (single-factor ANOVA, corrected P Ͻ 0.05). Functionally, they were related to metabolism (PTMA, PKN, and GALNT1) and transcription/RNA processing (BAT2D1 and RBM25).
WGCNA hub gene targeting. A few of the hubs (SAMD9L, EIF4A2, and PRPF4B) identified by WGCNA have been shown to be involved in aspects of cell migration and proliferation (see DISCUSSION) . Little has been published on SAMD9L; however, it has been previously shown to be substantially downregulated in invasive tumors, and its restoration correlated with a reduction in tumor invasion and proliferation (47) . Given the upregulation of SAMD9L expression after IFN stimulation and the known inhibitory effect of IFN on activated T cell migration (46), we postulated that SAMD9L may be a necessary component of the signaling pathway required to inhibit T cell migration. We tested this by gene silencing of SAMD9L using RNA interference and measured the effects on migration relative to IFN stimulation. RNA interference suppressed the IFN-stimulated expression (Fig. 5A, black) of SAMD9L in activated T cells relative to controls, with no effect on the expression of the unrelated IFN-stimulated gene MX1 (Fig. 5A, gray) . Moreover, the reduction in SAMD9L expression coincided with an increase in CXCL12-stimulated migration of activated T cells in a transwell assay (Fig. 5B) . Plotting the SAMD9L expression against the level of migration revealed an approximate plateau, indicating a saturable effect that is characteristic of biological interactions (Fig. 5B, inset) . In summary, our data suggests that SAMD9L expression is necessary for the inhibitory effect of IFN.
DISCUSSION
The precise mechanism of the variable, but undoubtedly beneficial, effects of IFNs in treating diseases like multiple sclerosis or cancer has not yet been clearly elucidated. This is at least partially due to the incompletely defined intracellular responses that IFN evokes within the various cell types implicated in disease pathogenesis. In efforts to increase our understanding of IFN signaling and the differential responses of type I IFNs, global transcriptional responses in isolated CD4 ϩ T cells were analyzed after IFN-␣ and IFN-␤ stimulation. We identified a set of 1,133 transcripts differentially expressed after treatment with either IFN (Fig. 1) .
Given the known subtype disparities in IFN cell signaling and therapeutic efficacies (see Introduction), we focused on IFN subtype differential responses to identify the regulatory patterns that may be relevant to an overarching biological mechanism, including enriched TFBSs and KEGG pathways.
Subtype-specific differences in observed transcription patterns were most often a result of inequalities in expression rates and ranges rather than in directions (Supplemental Fig. 2) . Nevertheless, we identified a small set of 12 genes uniquely downregulated by IFN-␤ (Supplemental Fig. 3 ). Among these was the chemokine receptor CX3CR1, previously recognized as a potential therapeutic target for autoimmune diseases (76) . Its ligand, CX3CL1 (fractalkine), has been reported to be elevated in the cerebrospinal fluid and serum of inflammatory diseases of the central nervous system (76) .
At the level of transcript regulation, we found enrichment for several TFBSs, many of which had been previously identified in inflammatory cascades and IFN signaling, thus vali- dating our chosen approach (Fig. 2) . These known transcription factors included common associations with the canonical IFNsensitive response element (7) and components of the IFN-␤ enhanceosome (60) (Fig. 2A ) and specific associations with STAT4 (43) and YY1 (29) . We also compared enriched TFBS to expression of the associated transcription factors. We found differential expression of several transcription factors over time, with a few significant subtype specific differences. These included KLF12 and IRF8.
KLF12, a transcription factor and repressor of the transcription factor AP-2␣, demonstrated an IFN-␣-specific decrease in expression after stimulation (Fig. 2C, inset, KLF12) . The transcription factor AP-2␣ plays a fundamental role in development, and its upregulation has been implicated in various forms of malignant transformation (22) , whereas its downregulation reduces tumor cell migration and invasion (58, 59) . The IFN-␣ specific downregulation of KLF12 could allow for enhanced transcription through AP-2␣ sites, promoting the transcription of genes favoring migration and proliferation. Indeed, concomitant with the IFN-␣-specific enrichment of the KLF12 TFBS was the specific association with the AP-2 TFBS (Fig. 2B ). More recently, KLF12 has been identified as a susceptibility gene for the autoimmune disorder rheumatoid arthritis (40) , suggesting a mechanism by which IFN-␣ might precipitate a treatment course with exacerbated side effects relative to IFN-␤, as seen in multiple sclerosis.
IRF8 demonstrated the most pronounced differential response, being one of a few transcripts to display opposing directions in its regulatory profile, namely, an IFN-␤-specific repression of expression (Fig. 2C, inset, IRF8 ). IRF8 (IFN consensus sequence-binding protein), in concert with IRF4, controls the transcription of immune-related genes and enhances IFN signaling in cells of hematopoietic lineage (42) , including the NF-B-dependent activation of CCL5 (48), a potent chemokine known to be elevated in the blood and cerebrospinal fluid of patients with multiple sclerosis (76) .
We also investigated the enrichment of KEGG pathways in the DEG transcripts and noticed marked subtype differences in the regulation of the JAK/STAT signaling pathway, APP pathway, and NKC pathway. Intriguingly, IFN-␤ led to a specific longitudinal downregulation of SOCS2 (Fig. 3 , JAK/ STAT pathway). SOCS2 has been shown to interfere with SOCS1 and SOCS3 by enhancing their ubiquitin-mediated degradation, acting as or facilitating a ubiquitin ligase (67) . The sharper decline and repression of SOCS2 levels after IFN-␤ stimulation could allow for the continued activity of both SOCS1 and SOC3 in the JAK/STAT pathway. Notably, the SOCS2 promoter contains TFBSs for both KLF12 and STAT5A homotetramers (a TFBS with a higher correlation to IFN-␣), two transcription factors that might contribute to the lag in repression after IFN-␣. STAT5A homotetramers, linked to leukemia (55) , have been shown to form more stable transcriptional activation complexes that can bind to weaker affinity sites and activate a broader range of transcripts (75) .
Within the APP pathway, we detected differential downregulation of MHC class II genes, where IFN-␤ elicited a more pronounced transcriptional repression (Fig. 3) . This disparity could be a consequence of the differential SOCS2 regulation, as the IFN-dependent negative regulator of MHC class II expression has been identified as SOCS1 (78) . By similar reasoning, the SOCS2 upregulation that has been demonstrated in peripheral T cells of rheumatoid arthritis maybe be in part responsible for the inflammatory exacerbations in rheumatoid arthritis through altered SOCS1 and MHC class regulation (38) .
Finally, we uncovered an IFN-␣-specific stimulation of gene expression associated with cytotoxic T cell phenotypes, including upregulation of the NKC pathway genes GZMA, GZMB, FASLG, FCGR3B, and IFNGR1 (2). Although a role for cytotoxic CD4
ϩ T cells in autoimmunity is largely unclear, they have been demonstrated to be expanded in the synovial tissues of rheumatoid arthritis (2) and in PBMCs of multiple sclerosis (53) .
While the regulatory patterns of individual genes and pathways were of interest, we also explored the expression patterns from the perspective of systems biology, thus viewing the genes as interconnected dynamic modules. We constructed network modules based on unbiased WGCNA and identified those highly connected nodes (hubs) within each module. WGCNA identified two modules (red and black) general to the IFN response and two modules (blue and deep pink) differentiating the IFN response. From these modules, we identified multiple general and specific hubs implicated in the regulation of cell proliferation and migration (Fig. 4) . These included SAMD9L, EIF4A2, PRPF4B, PKN2, and PTMA.
The general response hub SAMD9L has no known connections to the IFN response but has recently been shown to be downregulated in aggressive fibromatosis (47) and causes normophasphatemic familial tumoral calcinosis (NFTC) through unknown mechanisms (9) . Compared with other types of calcinosis, NTFC displays conspicuous inflammatory manifestations (9) . SAMD9L upregulation may in part explain the limited success of type I IFNs in treating various forms of cancer (65, 69) . Both IFNs upregulated SAMD9L after IFN stimulation, and we tested whether SAMD9L transcriptional inhibition by RNA interference could negate the inhibitory effect of IFN on migration. Indeed, SAMD9L RNA interference repressed gene expression (Fig. 5A) , and this coincided with a reduction in the CXCL12-stimulated migration of activated T cells (Fig. 5B) , thus, uniquely establishing its role in type I IFN signaling.
The subtype-specific hub genes EIF4A2 and PRPF4B are both linked to regulation and signal transduction by CCL5. EIF4A2 is a RNA helicase shown to be involved in protein translation via the eIF4F translational initiation complex and to be required for CCL5-mediated T cell chemotaxis (56) . Moreover, EIF4A2 is a positional candidate gene for type 2 diabetes (10). The hub gene PRPF4B is a protein kinase involved in mRNA splicing (17) and has been shown to be necessary for T cell CCL5 expression via KLF13 interactions (35) .
The hub gene PKN2 is a Rho-associated serine/threonine protein kinase with homology to PKC that controls the entry into mitosis and exit from cytokinesis (71) as well as the invasiveness of tumor cells (13) . The hub gene PTMA is small, highly acidic thymic peptide that affects a diverse array of cellular function including DNA packaging, apoptotic regulation, cell proliferation, and both the innate and adaptive immune responses (28, 68) . PTMA can upregulate MHC class II molecules on monocytes (5) and inhibit tumor growth (61) and, in combination with IFN-␣, has been used to effectively treat various cancers and chronic hepatitis B and C (23) .
Finally, the hub genes SP110 (72), GALNT1 (34) , and BAT2D1 (36, 52) have all been linked to various cancers, including breast (SP110 and GALNT) and bladder (BAT2D1) cancers, whereby their deregulation may allow for enhanced proliferation, invasion, and evasion of apoptosis.
By analyzing temporal expression patterns and contrasting evoked responses differential to IFN-␣ and IFN-␤, we were able to uncover new relationships and novel players involved in type I IFN signaling and function. By contrasting responses stimulated by each IFN subtype, a dominant theme emerged related to the known inhibitory effects of IFN on cell migration (Fig. 6) . Several of the proteins highlighted in this study have been shown to affect important aspects of migration, proliferation, and apoptosis. We also discovered IFN subtype differences that may relate to IFN stimulation of nonconventional CD4 ϩ T cell fates, namely, through the induction of proinflammatory signatures characteristic of CD4 ϩ cytotoxic T lymphocytes and a reduction in the machinery characteristics of APP.
In summary, by applying a genomic and systems-based approach to the analysis of longitudinal transcriptional data, we provide a foundation for the interpretation of the pleiotropic and differential effects of type I IFNs in humans. While these effects were studied in the context of CD4 ϩ T cells, the ubiquity of the IFN signaling pathway and its component proteins may allow for an extension of these findings to other cells type implicated in the pathogenesis of cancer, viral infection, and autoimmunity.
